Last updated: October 14, 2026
EULEXIN, the former Schering-Plough brand of flutamide, is a mature oral antiandrogen for prostate cancer. Its commercial trajectory moved from branded oncology revenue in the 1990s to generic commodity sales after patent and regulatory exclusivity ended. Current market value is limited, fragmented, and driven by low-cost generic flutamide rather than the EULEXIN brand.
The product has no meaningful biosimilar exposure, no material active patent barrier, and limited strategic importance for major pharmaceutical companies. Its principal risks are generic price erosion, declining clinical use relative to newer androgen-receptor pathway therapies, liver-toxicity monitoring requirements, and the availability of alternative antiandrogens.
What is EULEXIN and what drug does it contain?
EULEXIN contains flutamide, a nonsteroidal androgen-receptor antagonist. It was developed for use with a luteinizing hormone-releasing hormone, or LHRH, agonist in the treatment of metastatic prostate cancer. Flutamide blocks androgen stimulation of prostate-cancer cells but does not suppress testosterone production by itself.
| Product attribute |
EULEXIN status |
| Brand name |
EULEXIN |
| Active ingredient |
Flutamide |
| Original developer |
Schering-Plough |
| Dosage form |
125 mg oral capsule |
| Main indication |
Advanced or metastatic prostate cancer |
| FDA approval |
1989 |
| Regulatory category |
Small-molecule prescription drug |
| Current commercial model |
Generic flutamide |
| Biologic status |
Not applicable |
| Biosimilar risk |
None |
The FDA-approved regimen historically used 250 mg three times daily, generally in combination with an LHRH agonist. The product label warns of potentially severe hepatotoxicity and recommends liver-function monitoring, particularly during early treatment [1].
Flutamide was one of the earlier antiandrogens used in prostate cancer. It later faced competition from bicalutamide, nilutamide, abiraterone, enzalutamide, apalutamide, darolutamide, and other agents with different efficacy, safety, dosing, or convenience profiles.
When did EULEXIN lose exclusivity?
EULEXIN lost its commercial exclusivity after the underlying small-molecule protection and regulatory exclusivity periods expired. The FDA approved generic flutamide products, allowing multiple manufacturers to market the same active ingredient.
The exact commercial decline cannot be tied to a single public loss-of-exclusivity event because brand sales, patent expiry, generic approvals, and formulary substitution occurred across different periods. The relevant market transition was complete by the time flutamide became an established generic product.
EULEXIN FDA approval timeline
| Event |
Approximate timing |
Commercial consequence |
| FDA approval of EULEXIN |
1989 |
Launch of branded flutamide |
| Early prostate-cancer use |
1990s |
Brand oncology sales and combination use with LHRH therapy |
| Generic approvals |
Following expiration of applicable exclusivity |
Entry of multiple manufacturers |
| Post-generic period |
2000s onward |
Price compression and brand substitution |
| Current market |
Mature generic stage |
Limited brand economics and low strategic value |
The FDA’s Drugs@FDA database identifies EULEXIN under NDA 019886 and records its original approval history and labeling [2]. Current generic availability is reflected through FDA-approved flutamide products and the Orange Book [3].
What patents protect EULEXIN and flutamide?
No active patent estate appears to create a meaningful barrier to generic flutamide entry in the United States. EULEXIN is an old small-molecule product whose primary composition-of-matter and product protection periods expired decades ago.
Patent categories relevant to EULEXIN
| Patent category |
Current commercial relevance |
| Composition-of-matter patents |
Expired |
| Original formulation patents |
Expired or commercially immaterial |
| Method-of-use patents |
No material blocking protection identified |
| Manufacturing patents |
Potentially possible in theory, but not a barrier to standard generic supply |
| Orange Book-listed patents |
No active listing identified as a practical obstacle to generic entry |
| Pediatric exclusivity |
Not commercially relevant |
| Patent-term extension |
No current effect on market access |
The absence of meaningful patent protection does not prevent supply interruptions, product discontinuations, or manufacturer-specific regulatory restrictions. It does mean that an authorized generic or conventional ANDA applicant generally does not face the type of patent litigation associated with newer oncology products.
What is the Orange Book status of EULEXIN?
EULEXIN’s Orange Book significance is historical rather than defensive. The product is associated with an older NDA, while current market competition comes from abbreviated new drug applications for flutamide.
The Orange Book records approved drug products, therapeutic-equivalence evaluations, patents submitted for listing, and exclusivity information. For an old genericized product such as flutamide, the central commercial issue is whether approved generic products remain active and therapeutically equivalent, not whether an unexpired patent blocks entry [3].
A product may remain in FDA records even after the branded product is discontinued or no longer commercially promoted. Regulatory listing therefore should not be interpreted as evidence of material current brand revenue.
How many patents cover EULEXIN today?
No meaningful number of live, enforceable patents appears to cover the ordinary commercial use of EULEXIN or generic flutamide. The original patent portfolio is historical.
The more important distinction is between:
- Patents that once supported the original brand launch.
- Patents that may have protected specific formulations or manufacturing processes.
- Patents that could still block an ANDA applicant today.
For flutamide, the third category appears to have little practical significance. Generic manufacturers can compete without confronting a modern patent thicket covering dosage, delivery technology, crystal form, long-acting administration, or combination therapy.
What formulations are protected by EULEXIN patents?
The marketed EULEXIN product was an immediate-release oral capsule containing 125 mg of flutamide. There is no commercially important current patent barrier around a complex delivery system, extended-release platform, injectable formulation, or specialty dosage form.
This limits the possibility of preserving brand economics through lifecycle management. Unlike products with transdermal systems, long-acting injectables, inhalation devices, or proprietary delivery platforms, flutamide has a relatively simple oral presentation.
The formulation has practical disadvantages:
- Three-times-daily dosing in the historical regimen.
- Need for combination treatment with androgen-deprivation therapy.
- Liver-function monitoring.
- Limited differentiation from other oral antiandrogens.
- Low switching costs for prescribers and payers.
These characteristics favor generic substitution and reduce the commercial value of formulation-specific intellectual property.
What FDA regulatory status does EULEXIN have?
EULEXIN was approved for prostate-cancer treatment, but the clinical role of flutamide has narrowed as newer therapies entered the market. The drug remains a prescription medicine, while the brand’s commercial presence is substantially weaker than during its original launch period.
The FDA label identifies severe or fatal liver injury as a safety concern. Treatment is generally avoided or stopped when clinically significant liver abnormalities develop [1]. Safety monitoring increases the total treatment burden and reduces the product’s attractiveness when alternatives provide better clinical positioning.
Flutamide is not a biologic and does not proceed through the 351(k) biosimilar pathway. It is a conventional small molecule, so competition occurs through ANDAs and therapeutic equivalence rather than biosimilar applications.
Which companies are challenging EULEXIN?
There is no current high-profile Paragraph IV campaign comparable to litigation surrounding newer branded oncology drugs. The principal competitive challenge came from generic manufacturers entering after the relevant exclusivity period.
Generic competition
The FDA has historically approved multiple generic flutamide products. The manufacturer base can change because of discontinuations, supply decisions, manufacturing-site changes, or low commercial returns. Generic competition can therefore be broad at the regulatory level but narrow at the pharmacy-distribution level.
The key market participants are:
- Generic drug manufacturers holding or marketing flutamide ANDAs.
- Wholesalers and pharmacy suppliers.
- Institutional buyers treating prostate-cancer patients.
- Competing manufacturers of newer androgen-receptor pathway drugs.
The commercial challenge is not a branded patent dispute. It is substitution by lower-cost generics and clinical replacement by newer therapies.
What patent litigation affects EULEXIN?
No material ongoing patent litigation appears to affect EULEXIN or generic flutamide. The product’s age and lack of a meaningful blocking patent estate make modern Paragraph IV litigation unlikely.
Paragraph IV exposure
A Paragraph IV certification is relevant when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. For EULEXIN, the commercially significant generic-entry period has already occurred. Any historic Paragraph IV activity would have been associated with the original genericization phase rather than the present market.
The remaining litigation risks are more likely to involve:
- Product liability claims concerning hepatotoxicity.
- Manufacturing or quality disputes.
- Contracting and supply issues.
- Regulatory enforcement involving labeling or current good manufacturing practice.
These risks are different from patent-based exclusivity risks and generally do not preserve brand pricing.
How strong is the EULEXIN patent estate?
The current patent estate is weak from a market-exclusion perspective.
| Patent-strength factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Active Orange Book barrier |
No material barrier identified |
| Formulation differentiation |
Low |
| Delivery-system protection |
None of commercial importance |
| Method-of-use protection |
Limited practical value |
| Generic substitution risk |
High |
| Biosimilar risk |
Not applicable |
| Manufacturing barrier |
Low for standard oral capsules |
| Litigation leverage |
Low |
The patent estate may retain historical documentation value for due diligence, but it does not provide a credible basis for current premium pricing or licensing leverage.
How does EULEXIN compare with newer prostate-cancer drugs?
Flutamide competes in a category that has shifted toward more potent and clinically differentiated agents. The major comparison is no longer between EULEXIN and another legacy antiandrogen. It is between inexpensive generic therapy and newer branded drugs used across hormone-sensitive and castration-resistant prostate cancer settings.
| Product |
Mechanism or class |
Commercial position |
Key differentiation |
| Flutamide/EULEXIN |
First-generation androgen-receptor antagonist |
Generic, low price |
Established oral antiandrogen |
| Bicalutamide |
First-generation androgen-receptor antagonist |
Generic |
Longer practical dosing convenience |
| Abiraterone |
Androgen-biosynthesis inhibitor |
Branded and generic versions |
Hormonal pathway suppression |
| Enzalutamide |
Second-generation androgen-receptor inhibitor |
Branded oncology product |
Stronger receptor-pathway activity |
| Apalutamide |
Second-generation androgen-receptor inhibitor |
Branded |
Use in earlier prostate-cancer settings |
| Darolutamide |
Second-generation androgen-receptor inhibitor |
Branded |
Distinct pharmacologic and tolerability profile |
Newer agents have stronger clinical and commercial differentiation but carry much higher acquisition costs. Flutamide’s remaining use is more likely to reflect cost, historical familiarity, local practice, or limited access to newer drugs than competitive clinical superiority.
What is the financial trajectory of EULEXIN?
EULEXIN’s financial trajectory is a classic mature-product decline:
- Initial branded growth after FDA approval.
- Use in combination androgen-deprivation therapy.
- Competition from other antiandrogens.
- Generic entry and rapid price erosion.
- Reduced brand promotion and declining commercial relevance.
- Residual generic sales with limited manufacturer profitability.
Schering-Plough’s public financial reporting did not establish a durable, standalone revenue series for EULEXIN in the manner used for major contemporary oncology brands. Public company reports generally grouped products within broader therapeutic or geographic categories. As a result, current EULEXIN revenue cannot be reliably quantified from public filings.
Revenue exposure
| Revenue question |
Assessment |
| Current brand revenue |
Minimal or not separately reported |
| Generic flutamide revenue |
Distributed among manufacturers |
| Price trend |
Downward after generic entry |
| Volume trend |
Constrained by clinical substitution |
| Margin profile |
Low to moderate, depending on supply position |
| Strategic value |
Low |
| Licensing value |
Limited |
| Acquisition value |
Mainly supply-chain or portfolio-based |
There is no credible basis to treat EULEXIN as a material current revenue asset for a major pharmaceutical company. Any remaining value would depend on a specific manufacturer’s ability to maintain supply, secure contracts, or operate in a market with limited generic competition.
What generic launch scenarios exist for EULEXIN?
The most likely market scenarios are:
Continued low-volume generic supply
Several manufacturers may retain approval, but only a subset may actively market the product. Revenue would remain modest, with pricing shaped by pharmacy benefit managers, wholesalers, hospital contracts, and supply availability.
Supplier consolidation
If manufacturers exit because of low margins or manufacturing costs, the number of active suppliers could fall. Prices could temporarily rise, but the market would remain vulnerable to re-entry by other approved manufacturers.
Clinical displacement
Use could continue to decline as prescribers favor newer antiandrogens and more current prostate-cancer treatment algorithms. Clinical displacement is a stronger long-term risk than patent competition.
Brand discontinuation without therapeutic disappearance
The EULEXIN brand can disappear commercially while flutamide remains available as a generic. FDA regulatory records may continue to show the product or related approvals even when the original brand is not actively marketed.
What manufacturing and intellectual-property barriers affect flutamide?
Manufacturing flutamide does not require a complex delivery platform or biologic production process. The main barriers are operational rather than patent-based:
- Active pharmaceutical ingredient sourcing.
- Finished-dose manufacturing capacity.
- Quality-control testing.
- Stability and packaging compliance.
- FDA inspection status.
- Commercially viable batch sizes.
- Reliable distribution.
Manufacturers must also comply with current good manufacturing practice requirements and maintain approved product specifications. These obligations can cause supply interruptions, but they do not create durable market exclusivity.
Geographic manufacturing concentration can affect availability. A manufacturer with a single production site or a narrow API supply base may face higher interruption risk than a diversified supplier. This is a supply-chain issue, not an IP moat.
What is the geographic coverage of EULEXIN protection?
The original EULEXIN patent and regulatory position was jurisdiction-specific. Any historic protection in the United States, Europe, Japan, or other markets depended on local patent filing, examination, term calculation, and approval timing.
Current geographic commercial coverage is defined mainly by generic approvals:
- United States: FDA-approved generic flutamide products.
- Europe: National or centralized-market authorization history, depending on the product and country.
- Other markets: Local registrations and procurement systems determine availability.
There is no global EULEXIN patent estate that creates uniform international exclusivity. Market access and revenue depend on local generic registrations, reimbursement policy, clinical practice, and supplier participation.
Key Takeaways
- EULEXIN is the former Schering-Plough brand of flutamide, an oral nonsteroidal antiandrogen.
- FDA approval dates to 1989, making the product a mature generic medicine.
- The original composition, formulation, and regulatory exclusivity periods no longer provide meaningful market protection.
- No active patent barrier appears to prevent generic flutamide competition.
- Paragraph IV litigation is not a material current risk.
- Biosimilar competition does not apply because flutamide is a conventional small molecule.
- Severe hepatotoxicity warnings and three-times-daily historical dosing reduce clinical competitiveness.
- Newer agents such as enzalutamide, abiraterone, apalutamide, and darolutamide have displaced much of flutamide’s strategic role.
- Current brand revenue is minimal or not separately reported.
- Remaining value lies in low-cost generic supply, not in patent leverage, premium pricing, or licensing power.
FAQs About EULEXIN and Flutamide
Is EULEXIN still sold in the United States?
The EULEXIN brand has limited commercial relevance, while generic flutamide has historically remained the principal source of supply. FDA approval records do not necessarily indicate active brand marketing.
Does flutamide have patent protection today?
No meaningful active patent protection appears to block ordinary generic flutamide competition in the United States. Any relevant original patents expired long ago.
Is flutamide a biosimilar drug?
No. Flutamide is a synthetic small molecule approved through the conventional drug pathway. Generic products use ANDA-based approval, not the biosimilar pathway.
Why did physicians move away from EULEXIN?
Use declined because of liver-toxicity concerns, frequent dosing, limited differentiation, and the availability of newer prostate-cancer therapies with stronger clinical positioning.
Can EULEXIN generate licensing revenue?
A material licensing opportunity is unlikely. The brand has limited current commercial value, and the absence of a strong active patent estate reduces leverage in licensing negotiations.
References
- U.S. Food and Drug Administration. (n.d.). EULEXIN (flutamide) capsule prescribing information. FDA.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: EULEXIN, NDA 019886. FDA.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.
- National Cancer Institute. (n.d.). Flutamide. NCI Drug Dictionary.
- National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: Prostate cancer. NCCN.
